Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Liver metastases of colon cancer or rectal predominant (histological evidence obtained on the primary tumor or liver metastases)
Progression after first line chemotherapy to treat the metastatic disease, all types of treatment allowed except intra-arterial Bevacizumab
Age >18 years <75 years
Performance status WHO 0 or 1
Life expectancy >3 months
Bilirubin <1.5 times the upper limit of normal (N), ASAT and ALAT <5N, creatinine <1.5 N neutrophils >1.5 x 10^9/L, platelets ≥100 x 10^9/L, hemoglobin >9g/dL. Patients may be included even if they were transfused
CT (or MRI) reference for the measurement of metastases performed within 28 days before the first treatment cycle
Information of the patient or legal representative signing the informed consent
Affiliated to a social security system
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
10 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal